Valproate

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 685-697

  Bourgeois, Blaise F D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Generalized tonic clonic seizures; Hepatotoxic metabolite 4 ene valproic acid and cytochrome P450 enzymes; Infantile spasms and Lennox Gastaut syndrome; Myoclonic seizures; Pharmacodynamic drug interactions; Valproic acid small volume of distribution; Valproic acid and serum level drug increase; Valproic acid or valproate

Indexed keywords

EID: 84875254015     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch55     Document Type: Chapter

References (99)

1. Meunier H, Carraz G, Meunier V, Eymard M. Propriétés pharmacodynamiques de l'acide n-propylacétique. Thérapie 1963; 18: 435-438.
2. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-694.
3. Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 1999; 40: 1512-1522.
4. Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp Brain Res 2000; 133: 334-339.
5. Issakainen J, Bourgeois BF. Bioavailability of sodium valproate suppositories during repeated administration at steady-state in epileptic children. Eur J Pediatr 1987; 146: 404-407.
6. Sommerville KS, Dutta S, Biton V, Zhang Y, Cloyd JC, Uthman B. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin Drug Invest 2003; 23: 661-670.
7. Bourgeois BFD. Pharmacokinetics and pharmacodynamics of antiepileptic drugs. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2006:655-664.
8. Cloyd J, Kriel R, Jones-Saete C, et al. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr 1992; 120: 634-638.
9. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole-and multidrug therapy. Ther Drug Monit 1986; 8: 411-415.
10. Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 495-499.
11. Levy RH, Rettenmeier AW, Anderson GD. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-enevalproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48: 225-235.
12. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalitie. III. U.S. experience since 1986. Neurology 1996; 46: 465-469.
13. Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993; 53: 22-29.
14. Gal P, Oles KS, Gilman JT, Weaver R. Valproic acid efficacy, toxicity and pharmacokinetics in neonates with intractable seizures. Neurology 1988; 38: 467-471.
15. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy:general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-356.
16. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65: 504-523.
17. Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007; 39: 647-657.
18. Hooper WD, Franklin ME, Glue P, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of β-oxidation. Epilepsia 1996; 37: 91-97.
19. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55: 588-591.
20. Baumann RJ, Fakhoury TA, Kustra RP, Vuong A, Hammer AE, Messenheimer JA. Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. Curr Med Res Opin 2007; 23: 2461-2465.
21. Rathmalgoda C, Potter JM, Lueck CJ. Serum sodium valproate testing:is it appropriate? Med J Aust 2007; 187: 582-584.
22. Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JWA. The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 1979; 20: 61-68.
23. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.
24. Callaghan N, O'Hare J, O'Driscoll D, O'Neill B, Dally M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982; 24: 830-836.
25. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157-163.
26. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallelgroup study. Epilepsia 2004; 45: 1049-1053.
27. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 693-720.
28. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65: 504-523.
29. Feuerstein J. A long-term study of monotherapy with sodium valproate in primary generalized epilepsy. Br J Clin Pract 1983; 27(Suppl. 1):17-23.
30. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987; 28(Suppl. 2):S8-S11.
31. Ramsey RE, Wilder BJ, Murphy JV, Holmes GL, Uthman B. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. J Epilepsy 1992; 5: 55-60.
32. Spitz MC, Deasy DN. Conversion to valproate monotherapy in nonretarded adults with primary generalized tonic-clonic seizures. J Epilepsy 1991; 4: 33-38.
33. Wilder BJ, Ramsey RE, Murphy JV, et al. Comparison of valproic acid and phenytoin in newly-diagnosed tonic-clonic seizures. Neurology 1983; 33: 1474-1476.
34. Turnbull DM, Howel D, Rawlins MD, Chadwick DW. Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J 1985; 290:816-819.
35. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2005; (4): CD003032.
36. Dulac O, Steru D, Rey E, Arthius M. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986; 8: 47-52.
37. Fahn S. Post-anoxic action myoclonus: improvement with valproic acid. N Engl J Med 1978; 299: 313-314.
38. Bruni J, Willmore LJ, Wilder BJ. Treatment of postanoxic intention myoclonus with valproic acid. Can J Neurol Sci 1979; 6: 39-42.
39. Rollinson RD, Gilligam BS. Post-anoxic action myoclonus (Lance-Adams syndrome) responding to valproate. Arch Neurol 1979; 36: 44-45.
40. Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982; 39: 236-238.
41. Bachman DS. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39: 49-52.
42. Pavone L, Incorpora G, LaRosa M, LiVolti S, Mollica F. Treatment of infantile spasms with sodium dipropylacetic acid. Dev Med Child Neurol 1981; 23: 454-461.
43. Loiseau P, Cohadon S, Jogeix M, Legroux M, Artigues J. Efficacité du valproate de sodium dans les épilepsies partielles. Rev Neurol (Paris) 1984; 140: 434-437.
44. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639-644.
45. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982; 45: 55-59.
46. Dean JC, Penry JK. Valproate monotherapy in 30 patients with partial seizures. Epilepsia 1988; 29: 140-144.
47. Mattson RH, Cramer JA, Collins JF, Dept. of VA Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-771.
48. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentrationresponse design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology 1997; 48: 182-188.
49. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in pediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995; 37: 97-108.
50. DeSilva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347, 709-713.
51. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW, Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505-513.
52. Rantala H, Tarkka R, Uhari M. A meta-analytic review of the preventive treatment of recurrences of febrile seizures. J Pediatr 1997; 131: 922-925.
53. Lee K, Taudorf K, Hvorslev V. Prophylactic treatment with valproic acid or diazepam in children with febrile convulsions. Acta Paediatr Scand 1986; 75: 593-597.
54. Amann B, Grunze H, Vieta E, Trimble M. Antiepileptic drugs and mood stability. Clin EEG Neurosci 2007; 38: 116-123.
55. Yoon MS, Savidou I, Diener HC, Limmroth V. Evidence-based medicine in migraine prevention. Expert Rev Neurother 2005; 5: 333-341.
56. Silberstein SD. Valproic acid: clinical efficacy and use in other neurological disorders. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002: 818-827.
57. Swann AC. Valproic acid: clinical efficacy and use in psychiatric disorders. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002: 828-836.
58. Shin C, Gray L, Armond C. Reversible cerebral atrophy: radiologic correlate of valproate-induced Parkinson-dementia syndrome. Neurology 1992; 42(Suppl. 3): 277.
59. Marescaux C, Warter JM, Micheletti G, et al. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982; 23: 297-305.
60. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002; 17: 367-373.
61. Bauer J. Encephalopathy induced by levetiracetam added to valproate. Acta Neurol Scand 2008; 117: 374-376.
62. Sommerbeck KW, Theilgaard A, Rasmussen KE, et al. Valproate sodium:evaluation of so-called psychotropic effect. A controlled study. Epilepsia 1977; 18: 159-167.
63. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-177.
64. Pylvänen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003; 60: 571-574.
65. Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 2005; 65: 1808-1809.
66. Pylvänen V, Pakarinen AJ, Knip M, Isojärvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006; 47: 1460-1464.
67. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine-a reappraisal. Seizure 1997; 6: 121-125.
68. Sewell AC, Bohles HJ, Herwig J, Demirkol M. Neurological deterioration in patients with urea cycle disorders under valproate therapy-a cause for concern. Eur J Pediatr 1995; 154: 593-594.
69. Pellock JM, Willmore LJ, Privitera MD. Routine monitoring for safety and tolerability during chronic treatment with antiepileptic drugs. In. Engel J Jr and Pedley T (eds). Epilepsy. A Comprehensive Textbook. Philadelphia: Lippincott Williams & Wilkins, 2008: 1311-1316.
70. Sugimoto T, Muro H, Woo M, Nishida N, Murakami K. Metabolite profiles in patients on high-dose valproate monotherapy. Epilepsy Res 1996; 25: 107-112.
71. Bohan TP, Helton E, Mcdonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56: 1405-1409.
72. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998; 39: 1216-1225.
73. Asconapé JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproateassociated pancreatitis. Epilepsia 1993; 34: 177-183.
74. Grauso-Eby NL, Goldfarb O, Feldman-Winter LB, McAbee GN. Acute pancreatitis in children from valproic acid: case series and review. Pediatr Neurol 2003; 28: 145-148.
75. Bale JF, Gay PE, Madsen JA. Monitoring of serum amylase levels during valproic acid therapy. Ann Neurol 1982; 11: 217-218.
76. Otusbo S, Huruzono T, Kobae H, Yoshimi S, Miyata K. Pancreatitis with normal serum amylase associated with sodium valproate case report. Brain Dev 1995; 17: 219-221.
77. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-65.
78. Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a propsepctive monotherapy study. Epilepsia 2008; 49: 438-445.
79. Pohlmann-Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003; 108: 142-145.
80. Teich M, Longin E, Dempfle CE, Konig S. Factor XIII deficiency associated with valproate treatment. Epilepsia 2004; 45: 187-189.
81. Winter SL, Kriel RL, Novachec TF, et al. Perioperative blood loss: the effect of valproate. Pediatr Neurol 1996; 15: 19-22.
82. Ward MM, Barbaro NM, Laxer KD, Rampil IJ. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996; 37: 98-101.
83. Anderson GD, Lin YX, Berge C, Ojemann G. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997; 87: 252-256.
84. Chicharro AV, de Marinis AJ, Kanner AM. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy Behav 2007; 11: 361-366.
85. Gidal BE, Inglese CM, Meyer JF, et al. Diet-and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol 1997; 16: 301-305.
86. Laub MC, Paetake-Brunner I, Jaeger G. Serum carnitine during valproate acid therapy. Epilepsia 1986; 27(Suppl. 5): 559-562.
87. Murakami K, Sugimoto T, Woo M, Nishida N, Muro H. Effect of Lcarnitine supplementation on acute valproate intoxication. Epilepsia 1996; 37: 687-689.
88. Isojärvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001; 111: 290-296.
89. Luef G, Abraham I, Trinka E, et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Research 2002a; 48: 91-102.
90. Genton P, Bauer J, Duncan S, et al. On the association of valproate and polycystic ovaries. Epilepsia 2001; 42: 295-304.
91. Isojärvi JI, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: A response and an alternative view. Epilepsia 2001; 42: 305-310.
92. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 2003; 63: 1185-1227.
93. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961-965.
94. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61(Suppl. 2):S23-S26.
95. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575-1583.
96. Branten AJ, Wetzels JF, Weber AM, Koene RA. Hyponatremia due to sodium valproate. Ann Neurol 1998; 43: 265-267.
97. Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A. Hyponatremia associated with sodium valproate in a 22-year-old male. Nephrol Dial Transpl 2008; 23: 410.
98. Boggs JG, Preis K. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit. Epilepsia 2005; 46: 949-951.
99. Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64: 353-355.